InMed Pharmaceuticals Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023, filed September 29, 2023. The requested “2022 Q4” period does not match this annual filing. All amounts are in U.S. dollars unless stated otherwise.
Business Context and Reporting Period
InMed is a Canadian clinical-stage pharmaceutical company developing synthetically manufactured rare-cannabinoid and cannabinoid-analog therapies. Its lead programs are INM-755, a topical cannabinol cream for epidermolysis bullosa, and INM-088, a cannabinol eye-drop candidate for glaucoma. The INM-900 series is in discovery/preclinical development for neurodegenerative diseases.
Through BayMedica, a wholly owned subsidiary, the Company sells rare cannabinoids to business-to-business customers in the health and wellness sector. InMed has no FDA-approved pharmaceutical products and depends primarily on equity financings and BayMedica product sales to fund operations.
Financial Metrics
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Sales | $4.14 million | $1.09 million | +280% |
| Gross profit | $1.40 million | $0.54 million | +158% |
| Gross margin | Approximately 34% | Approximately 50% | Lower due to product mix and inventory write-down |
| Net loss | $7.95 million | $18.60 million | Loss reduced by $10.65 million |
| Operating expenses | $9.78 million | $17.81 million | Down $8.03 million |
| Cash used in operating activities | $7.28 million | $15.58 million | Improved by $8.30 million |
| Cash, cash equivalents and short-term investments | $8.96 million | $6.22 million | Increased by approximately $2.74 million |
| Accumulated deficit | $101.40 million | $93.45 million | Increased by $7.95 million |
BayMedica generated $4.14 million of sales and $1.40 million of gross profit. Cost of sales was $2.42 million, and the Company recorded a $0.31 million inventory write-down due to lower demand and pricing pressure. BayMedica reported a segment net loss of $1.21 million; the InMed pharmaceutical segment reported a net loss of $6.74 million.
Financing activities provided $10.68 million, consisting primarily of $12.0 million of gross proceeds from private placements, partially offset by $1.32 million of issuance costs. The balance sheet showed total liabilities of $2.02 million, including approximately $0.39 million of lease obligations; the filing does not identify material conventional debt outstanding.
Material Changes Versus the Prior Comparable Period
- BayMedica sales increased substantially from $1.09 million to $4.14 million, with management citing increased marketing and demand for selected rare-cannabinoid products.
- Research and development and patent expenses declined to $3.73 million from $7.28 million, largely because FY2022 included significant start-up costs for the INM-755 Phase 2 trial.
- General and administrative expenses declined to $5.85 million from $6.87 million.
- FY2022 included $3.47 million of impairment charges for BayMedica goodwill and intangible assets and $1.31 million of warrant modification expense; neither item recurred in FY2023.
- FY2023 included a $0.31 million inventory write-down and higher BayMedica commercial costs.
- Common shares outstanding increased from 650,667 at June 30, 2022 to 3,328,191 at June 30, 2023, reflecting equity financings and warrant exercises, among other items.
Guidance, Outlook, Risks and Unusual Items
Management expects continued operating losses and negative operating cash flow. At the filing date, the Company estimated that its approximately $9.0 million of cash, cash equivalents and short-term investments would fund operations into approximately the first quarter of calendar 2024, depending on BayMedica revenue and spending levels. The auditors and management concluded that substantial doubt exists regarding the Company’s ability to continue as a going concern within one year after issuance of the financial statements.
The INM-755 Phase 2 trial enrolled 19 patients and completed treatment in April 2023. Preliminary results indicated clinically meaningful anti-itch activity in some patients, but the small trial did not produce statistically significant results for non-wound itch. No serious drug-related adverse events were reported. Full data was expected in the second quarter of fiscal 2024. The Company is seeking research and commercial partners for continued development.
INM-088 remains preclinical. The Company reported encouraging animal and laboratory findings involving intraocular-pressure reduction and neuroprotection, but these results do not establish clinical efficacy or regulatory approval. The INM-900 program remains in discovery and preclinical candidate-selection work.
Key risks include the need for additional financing and potential shareholder dilution; clinical, regulatory and commercialization failure; difficulty enrolling patients; dependence on contract manufacturers and collaborators; uncertainty over the scalability and economics of the IntegraSyn platform; competition; controlled-substance restrictions; inventory demand and pricing pressure; and limited operating resources.
Management reported that disclosure controls and internal control over financial reporting were not effective as of June 30, 2023 because of a material weakness involving inadequate accounting personnel and segregation of duties following employee turnover. A remediation plan and outside financial support were underway.
BayMedica disclosed a dispute with a patent licensor alleging breach of a license agreement. The Company disputed the allegation; no lawsuit had been filed, and the potential loss could not be reasonably estimated. In addition, Nasdaq notified the Company in September 2023 that its average closing bid price was below $1.00. The Company received a 180-day period to regain compliance, subject to possible appeal and delisting risk.
Most Important Facts for Investors to Verify
- Current cash runway, subsequent financings, and whether additional equity or strategic funding has been obtained.
- Whether BayMedica’s sales growth and gross margins are sustainable amid pricing pressure and customer concentration.
- Complete INM-755 Phase 2 data, statistical results, safety profile, and the status of a development or commercial partner.
- Regulatory and clinical milestones for INM-088 and the INM-900 series.
- Progress in remediating the material weakness in internal control over financial reporting.
- Nasdaq minimum-bid-price compliance and any reverse split, appeal, or delisting developments.
- The status and potential financial impact of the BayMedica patent-license dispute.
- Potential dilution from outstanding warrants, preferred investment options, stock options, and future capital raises.